Clinical Trial Update: A 24 Week Open Label Study of the Utility of Adalimumab in Active Axial Forms of Psoriatic Arthritis

View source ↗

Summary

A 24-week open-label study evaluated the use of adalimumab for active axial psoriatic arthritis; the trial has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)

Snippet

Sponsor: Dr. FRANCISCO J. BLANCO-GARCIA | Conditions: Psoriatic Arthritis | Status: COMPLETED